Almac Completes Its Expansion Plan to Pharma Services Facilities
Almac’s Pharma Services
business unit has announced the completion of a $13.75 million expansion to the company’s existing facilities at the Group’s headquarters in Craigavon, Northern Ireland.
The completion of a three story extension to the existing commercial manufacture facility in June 2009 expanded Pharma Services’ laboratory and office areas by 30,000 ft2. The new laboratories aim to enhance the existing analytical and microbiological drug product support services.
Remodelling of the now 120,000 ft2 commercial manufacture facility was completed in March 2010. Remodeling included expansion in microbiological and sterility test areas, new yellow light labs, and office and meeting room expansion. Method development, validation, and transfer supporting multiple client projects, are offered over a wide range of technologies from our expanded facility.
Graeme McBurney, President & M.D of Almac Pharma Services commented: “Increased client demand for our integrated services has resulted in the strategic decision to make this investment and expansion, both in terms of space and the additional team members we are recruiting. I look forward to working with the current and new members of our team.”
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
